Gavel About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Alza Corp. et al. v. Mylan Pharmaceuticals Inc. et al.
1:14-cv-00085; filed May 15, 2014 in the Northern District of West Virginia

• Plaintiffs:  Alza Corp.; Janssen Pharmaceuticals, Inc.
• Defendants:  Mylan Pharmaceuticals Inc.; Mylan Inc.

Alza Corp. et al. v. Mylan Pharmaceuticals Inc. et al.
1:14-cv-00594; filed May 12, 2014 in the District Court of Delaware

• Plaintiffs: Alza Corp.; Janssen Pharmaceuticals Inc.
• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc.

The complaints in these cases are substantially identical.  Infringement of U.S. Patent No. 8,163,798 ("Methods and Devices for Providing Prolonged Drug Therapy," issued April 24, 2012) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Alza's Concerta® (methylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder).  View the Mylan complaint here.

Cephalon Inc. v. InnoPharma Inc.
1:14-cv-00590; filed May 9, 2014 in the District Court of Delaware

Infringement of U.S. Patent No. 8,609,863 ("Bendamustine Pharmaceutical Compositions," issued December 17, 2013) following a Paragraph IV certification as part of InnoPharma's filing of an ANDA to manufacture a generic version of Cephalon's Treanda® (bendamustine hydrochloride, used to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma).  View the complaint here.

Otsuka Pharmaceutical Co. v. Alembic Pharmaceuticals Ltd. et al.
1:14-cv-02982; filed May 9, 2014 in the District Court of New Jersey

• Plaintiff: Otsuka Pharmaceutical Co.
• Defendants: Alembic Pharmaceuticals Ltd.; Alembic Ltd.; Alembic Global Holding SA; Alembic Pharmaceuticals Inc.

Infringement of U.S. Patent Nos. 8,017,615 ("Low Hygroscopic Aripiprazole Drug Substance and Process for the Preparation Thereof," issued September 13, 2011), 8,580,796 (same title, issued November 12, 2013), 8,642,760 (same title, issued February 4, 2014), and 8,518,421 ("Flashmelt Oral Dosage Formulation," issued August 27, 2013) following a Paragraph IV certification as part of Alembic's filing of an ANDA to manufacture a generic version of Otsuka's Abilify® (aripiprazole, used to treat bipolar disorder and schizophrenia).  View the complaint here.

Topics:  Cephalon, Mylan Pharmaceuticals, Patent Infringement, Patent Litigation, Patents, Pharmaceutical, Pharmaceutical Patents

Published In: Intellectual Property Updates, Science, Computers & Technology Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »

CONNECT

At McDonnell Boehnen Hulbert & Berghoff LLP ("MBHB"), we provide creative, pragmatic business... View Profile »


Follow McDonnell Boehnen Hulbert & Berghoff LLP:

Reporters on Deadline